STAR is a major methodological advance for Sjögren’s disease because it was designed to overcome long-standing limitations of previous trial endpoints, namely high placebo responses, fragmented assessment of symptoms versus systemic activity, and the failure to capture glandular and biological changes in a single measure. Developed using re-analyses of nine randomised trials and extensive consensus work with clinicians, scientists, and patients, STAR integrates five core disease domains, systemic activity, patient-reported symptoms, glandular function, and biological markers, into one composite responder index intended for use as a primary endpoint in clinical trials. Its planned influence is to improve the sensitivity and credibility of efficacy assessments, enable detection of therapeutic benefit across the full spectrum of patients (including those with high symptom burden but low systemic activity), and facilitate regulatory acceptance by providing a rigorous, patient-relevant, and globally interpretable outcome measure; ultimately accelerating drug development and the likelihood that disease-modifying therapies for Sjögren’s syndrome can be demonstrated and approved.